insights_auto
Why is 532523 up 2.60%?
Dive Deeperchevron_right
532523:BOM
Biocon Ltd
â‚ą395.00
arrow_upward
+2.60%(+10.00) 1D
Sep 21, 3:50:07 PM GMT+5:30 · INR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 532523...
Open
â‚ą387.55
High
â‚ą396.00
Low
â‚ą387.55
Mkt. cap
473.31B
Avg. vol.
0.00
Volume
105.48K
Dividend
0.13%
Quarterly dividend
â‚ą0.13
Ex-dividend date
Jul 3, 2026
P/E ratio
116.94
52-wk high
â‚ą447.00
52-wk low
â‚ą337.20
EPS
â‚ą3.38
Shares outstanding
600.00M
No. of employees
16K
Open
â‚ą387.55
High
â‚ą396.00
Low
â‚ą387.55
Mkt. cap
473.31B
Avg. vol.
0.00
Volume
105.48K
Dividend
0.13%
Quarterly dividend
â‚ą0.13
Ex-dividend date
Jul 3, 2026
P/E ratio
116.94
52-wk high
â‚ą447.00
52-wk low
â‚ą337.20
EPS
â‚ą3.38
Shares outstanding
600.00M
No. of employees
16K
News stories
From web sources and news partners
Business Standard
·
17 hours ago
Biocon spurts 3% as Pertuzumab drug moves closer to marketing nod in Europe
TipRanks
·
17 hours ago
Biocon’s Pertuzumab Biosimilar Wins Key EMA CHMP Backing Under New Regulatory Path
Business Standard
·
19 hours ago
Biocon Biologics receives positive CHMP opinion for Pertuzumab biosimilar
AD HOC NEWS
·
2 days ago
Biocon stock holds steady as investors digest Q1 FY27 earnings
Profile
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
About Biocon Ltd
CEOShreehas P Tambe
Employees16.4K
FoundedNov 29, 1978
HeadquartersBengaluru, Karnataka, India
SectorBiotechnology
Websitebiocon.com